secwatch.observer — SEC 8-K summary
======================================

Issuer:     IDEAYA Biosciences, Inc. (IDYA)
CIK:        0001676725
Form:       8-K
Filed at:   2025-02-10T23:59:59+00:00
Accession:  0001193125-25-023076
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

IDEAYA appoints Joshua Bleharski as CFO, effective May 2025
-----------------------------------------------------------

- Joshua Bleharski, Ph.D., age 50, appointed Chief Financial Officer, effective early May 2025.
- Bleharski joins from J.P. Morgan, where he spent 17 years, most recently as Managing Director and Global Co-Head of Biopharma.
- Holds B.S. in Biology from Duke, Ph.D. in Immunology from UCLA, and MBA from UC Berkeley Haas.
- Compensation terms for Bleharski will be disclosed later via an amendment to this Form 8-K.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1676725/000119312525023076/0001193125-25-023076-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1676725/000119312525023076/d934896d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-023076

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer